A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | MicrobiomeTrials

← Back to trials

NCT04658862

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2020-12-07Est. Completion: 2026-12-30

Enrollment target: 518 participants

Locations

Loma Linda Univ Faculty Medic, Loma Linda, California, United States
University of Southern California, Los Angeles, California, United States
Providence Saint John s Health Center, Santa Monica, California, United States
Stanford University Medical Center, Stanford, California, United States
The Urology Center of Colorado, Denver, Colorado, United States
Foothills Urology - Golden Off, Golden, Colorado, United States
Boca Raton Regional Hospital, Boca Raton, Florida, United States
Urological Research Network, Hialeah, Florida, United States
Memorial Healthcare System, Pembroke Pines, Florida, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
DuPage Medical Group, Lisle, Illinois, United States
University Hospitals Seidman Cancer Center, Ann Arbor, Michigan, United States
Michigan Institute of Urology, Troy, Michigan, United States
Adult Pediatric Urology & Urogynecology, P.C, Omaha, Nebraska, United States
Garden State Urology, Morristown, New Jersey, United States

Other microbiome trials you might be interested in

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active SurveillancePhase 2Recruiting

AdenocarcinomaProstate CancerNeoplasmsCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Background: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Ear…

Bethesda, United StatesEst. completion Jun 15, 2027

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid TumorsPhase 2Recruiting

Stage IV Bladder Urothelial CarcinomaProstate Cancer

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.